C4X Discovery Holdings PLC Appointment of Dr Cathy Tralau-Stewart as CSO (2587W)
21 December 2021 - 5:59PM
UK Regulatory
TIDMC4XD
RNS Number : 2587W
C4X Discovery Holdings PLC
21 December 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Dr Catherine Tralau-Stewart Appointed as C4XD's Chief Scientific
Officer
21 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, today announces the appointment
of Dr Catherine Jane Tralau-Stewart, PhD, FRSC, as Chief Scientific
Officer ("CSO"), as of 4 January 2022.
Cathy joins C4XD with more than 20 years of senior academic and
industry leadership experience. Her broad and in-depth knowledge of
drug discovery and translation of early research innovation into
robust drug discovery programmes has enabled the development of
scientific portfolios as well as the design and negotiation of many
initiatives to support effective decision-making. Previously she
was Senior Director, Alliances, for Takeda Pharmaceuticals where
she was responsible for and contributed to the strategic
development and management of academic alliances for Takeda for the
US, Australia, Japan and Europe. Having started her career at GSK,
she moved into academia where she held senior leadership roles
building drug discovery portfolios through to Phase III clinical
studies, at Imperial College London, University of California San
Francisco and Stanford University-Takeda Alliance for Innovative
Medicines.
Cathy has a BSc (Hons) Biological Sciences
(Biochemistry/Pharmacology) and a PhD (Clinical Sciences)
University College Hospital Medical School, National Medical Laser
Centre, Dept. of Surgery and ICRF (CRUK). She has been involved in
advising on, evaluation and due diligence of over 500 projects and
has supported and facilitated the translation of over 40
therapeutic technologies towards the clinic from academia and
delivered strategies with effective milestone driven
decision-making. Cathy is expert in transforming therapeutics
projects from target identification and validation through lead
optimisation to Clinical Proof of Concept in many therapeutic areas
including Inflammation and Neurosciences. She has published more
than 25 publications and is the inventor of three granted patents
and is a non-inventor contributor of many more.
Cathy received the President's award of Fellow Royal Society of
Chemistry (FRSC), is International Meeting Chair 2022 &
Previous Invited Board Director Society of Laboratory Screening
& Automation (SLAS), Fellow of SLAS, Member of British
Pharmacological Society, is currently supporting the development of
Closed Loop Medicine's commercial Steering Group and has acted as
advisor to many academic entrepreneurship & commercialization
programmes including Stanford SPARK, UCSF, UCLA, UCSD, UC Davis and
the NIH.
Clive Dix, Chief Executive Officer of C4X Discovery, commented:
"Cathy is a highly respected scientific leader with strong and deep
drug discovery expertise and we are delighted and proud that she
will be joining the team here at C4XD. Her experience in building
drug discovery portfolios and advancing programmes into clinical
development will enhance the work of the team here at C4XD and
expand our portfolio through her strong academic and industry
network. We warmly welcome Cathy and look forward to working
alongside her."
Cathy Tralau-Stewart added: "This is a fantastic opportunity to
work at an innovative, Drug Discovery company with cutting-edge
technologies and an inspirational scientific team. C4XD has made
incredible progress to date and I am excited to be joining the team
to build on and advance the portfolio towards future commercial
partnership that could improve the lives of patients in need of new
treatment options."
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel
target opportunities to late-stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPGGUPUPGGMU
(END) Dow Jones Newswires
December 21, 2021 01:59 ET (06:59 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024